Methods for monitoring molecular biomarkers for aging and disease
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsVinit MAHAJAN, Julian WOLF
Life of this patent
Estimating the term…
Abstract
Compositions, methods, and kits are provided for diagnosing vitreoretinal diseases and age-related pathologies. In particular, aqueous humor biomarkers have been identified that correlate with biological aging and age-related pathologies and morbidity. The use of such biomarkers may allow earlier intervention in treatment of aging-related diseases. In addition, methods of using aqueous humor biomarkers for prognosis, diagnosis, and monitoring treatment of vitreoretinal diseases are also provided.
Claims37
A method of diagnosing and treating age-related macular degeneration (AMD) in a patient, the method comprising:
- obtaining an aqueous humor sample from an eye of the patient;
- measuring levels of one or more biomarkers selected from serpin family F member 1 (SERPINF1), vascular endothelial growth factor A (VEGFA), fins related receptor tyrosine kinase 1 (FLT1), vascular endothelial growth factor B (VEGFB), and vascular endothelial growth factor D (VEGFD) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from SERPINF1, VEGFA, FLT1, VEGFB, and VEGFD compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has AMD;
- and
- treating the patient for the AMD if the patient has a positive diagnosis for AMD.
(canceled)
5-18. (canceled)
A method of diagnosing and treating diabetic retinopathy in a patient, the method comprising:
- obtaining an aqueous humor sample from an eye of the patient;
- measuring levels of one or more biomarkers selected from serpin family F member 1 (SERPINF1), retinoic acid receptor responder 2 (RARRES2), complement factor I (CFI), amyloid beta precursor protein (APP), complement C4A (C4A), and complement C4B (C4B) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from SERPINF1, RARRES2, CFI, APP, C4A, and C4B compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has diabetic retinopathy;
- and
- treating the patient for the diabetic retinopathy if the patient has a positive diagnosis for diabetic retinopathy.
(canceled)
23-38. (canceled)
A method of diagnosing and treating proliferative vitreoretinopathy (PVR) in a patient, the method comprising:
- obtaining an aqueous humor sample from an eye of the patient;
- measuring levels of one or more biomarkers selected from insulin like growth factor binding protein 6 (IGFBP6), C-C motif chemokine ligand 15 (CCL15), C-X-C motif chemokine ligand 12 (CXCL12), vascular endothelial growth factor A (VEGFA), and C-C motif chemokine ligand 23 (CCL23) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from IGFBP6, CCL15, CXCL12, VEGFA, and CCL23 compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has PVR;
- and
- treating the patient for the PVR if the patient has a positive diagnosis for PVR.
(canceled)
43-56. (canceled)
A method of diagnosing and treating melanoma in a patient, the method comprising:
- obtaining an aqueous humor sample from an eye of the patient;
- measuring levels of one or more biomarkers selected from follistatin like 1 (FSTL1), ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), angiogenin (ANG), MET proto-oncogene, receptor tyrosine kinase (MET), and hepatocyte growth factor (HGF) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from FSTL1, ENPP2, ANG, MET, and HGF compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has melanoma;
- and
- treating the patient for the melanoma if the patient has a positive diagnosis for melanoma.
(canceled)
62-77. (canceled)
A method of diagnosing and treating uveitis in a patient, the method comprising:
- obtaining an aqueous humor sample from an eye of the patient;
- measuring levels of one or more biomarkers selected from retinoic acid receptor responder 2 (RARRES2), biotinidase (BTD), cystatin C (CST3), TIMP metallopeptidase inhibitor 2 (TIMP2), and prostaglandin D2 synthase (PTGDS) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from RARRES2, BTD, CST3, TIMP2, and PTGDS compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has uveitis;
- and
- treating the patient for the uveitis if the patient has a positive diagnosis for uveitis.
(canceled)
82-95. (canceled)
A method of diagnosing and treating neovascular inflammatory vitreoretinopathy (NIV) in a patient, the method comprising:
- obtaining an aqueous humor sample from an eye of the patient;
- measuring levels of one or more biomarkers selected from serpin family C member 1 (SERPINC1), hemopexin (HPX), coagulation factor II (F2), complement C9 (C9), and complement C6 (C6) in the aqueous humor sample, wherein increased levels of the one or more biomarkers selected from SERPINC1, HPX, F2, C9, and C6 compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has neovascular inflammatory vitreoretinopathy (NIV);
- and
- treating the patient for the neovascular inflammatory vitreoretinopathy (NIV) if the patient has a positive diagnosis for neovascular inflammatory vitreoretinopathy (NIV).
(canceled)
100-113. (canceled)
A method of predicting biological age and determining risk of age-related pathology and morbidity in a patient, the method comprising:
- obtaining an aqueous humor sample from an eye of the patient;
- measuring levels of one or more biomarkers selected from stromelysin-2 (MMP10), neuropilin-1 (NRP1), semaphorin 3C (SEMA3C), hes family bHLH transcription factor 5 (HES5), and fibroblast growth factor receptor like 1 (FGFRL1) in the aqueous humor sample, wherein decreased levels of the one or more biomarkers selected from MMP10, NRP1, SEMA3C, HES5, and FGFRL1 compared to reference value ranges for the levels of the one or more biomarkers in a control aqueous humor sample indicate that the patient has a risk of age-related pathology and morbidity;
- and
- increasing screening of the patient for an aging-related disease if the patient is identified as having the risk age-related pathology and morbidity.
A method of monitoring biological aging of an eye in a patient, the method comprising:
- obtaining an aqueous humor sample from an eye of the patient;
- and
- measuring levels of one or more biomarkers selected from stromelysin-2 (MMP10), neuropilin-1 (NRP1), semaphorin 3C (SEMA3C), hes family bHLH transcription factor 5 (HES5), and fibroblast growth factor receptor like 1 (FGFRL1) in the aqueous humor sample, wherein levels of the one or more biomarkers selected from MMP10, NRP1, SEMA3C, HES5, and FGFRL1 are correlated with biological age of the eye.
(canceled)
119-128. (canceled)
Dependencies are inferred from the claim text.